You are here

FDA Approves Adenosine Injection

JERUSALEM--(BUSINESS WIRE)--June 16, 2004--June 16, 2004--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA - News) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Adenosine Injection USP, 3 mg/mL, which was submitted by the Company's subsidiary SICOR Inc. Shipment of this product, which has been approved in 2 mL and 4 mL vials, is expected to begin immediately.

Teva's Adenosine Injection USP is the generic equivalent of Fujisawa's Adenocard (R) Injection. This product is indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome).

The brand product has annual sales of approximately $13 million.

Source: Teva Pharmaceutical Industries

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
So far in January, the increases average 5%
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers